Although overall the second quarter financial report filings of biotech companies received a modest passing grade, investors were lukewarm to those less than stellar performances. That general angst was one of the contributing factors for the pullback in biotech during August. Read More
The fears that the downward spiral of the capital markets during the financial crisis that occurred in 2008 would be repeated in the wake of last week's "Black Monday" are, for the time being, in the rearview mirror. In fact, the markets have rebounded strongly and now seem poised to remain positive for the final months of the year, although it is predicted there will be some turbulence along the way. Read More
